NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis $28.00 -0.53 (-1.86%) As of 07/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Damora Therapeutics, Inc. Common Stock Stock (NASDAQ:DMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DMRA alerts:Sign Up Key Stats Today's Range$26.29▼$28.9150-Day Range$20.07▼$30.7852-Week Range$2.45▼$38.33Volume269,779 shsAverage Volume945,739 shsMarket Capitalization$1.72 billionP/E RatioN/ADividend YieldN/APrice Target$42.43Consensus RatingModerate Buy Company Overview Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue. Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment. Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.AI Generated. May Contain Errors. Read More Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreDMRA MarketRank™: Damora Therapeutics, Inc. Common Stock scored higher than 53% of companies evaluated by MarketBeat, and ranked 487th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingDamora Therapeutics, Inc. Common Stock has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDamora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, representing about 51.5% upside from its current price of $28.00.Amount of Analyst CoverageDamora Therapeutics, Inc. Common Stock has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Damora Therapeutics, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($1.92) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Damora Therapeutics, Inc. Common Stock's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.82% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverDamora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 2.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Damora Therapeutics, Inc. Common Stock has recently increased by 172.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDamora Therapeutics, Inc. Common Stock does not currently pay a dividend.Dividend GrowthDamora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.12 News SentimentDamora Therapeutics, Inc. Common Stock has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 3 articles on an average week. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Damora Therapeutics, Inc. Common Stock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,345.00 in company stock.Percentage Held by Insiders0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.Percentage Held by Institutions14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.Read more about Damora Therapeutics, Inc. Common Stock's insider trading history. Receive DMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Damora Therapeutics, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMRA Stock News HeadlinesDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Recommendation of "Moderate Buy" by Analysts1 hour ago | americanbankingnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2026 | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 14 at 1:00 AM | Reagan Gold Group (Ad)Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comDamora Therapeutics: Well-Funded Moonshot For CALR MutationsMay 27, 2026 | seekingalpha.comDamora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | globenewswire.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comDamora Therapeutics Inc.April 24, 2026 | barrons.comSee More Headlines DMRA Stock Analysis - Frequently Asked Questions How have DMRA shares performed this year? Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 at the beginning of the year. Since then, DMRA shares have increased by 21.7% and is now trading at $28.00. How were Damora Therapeutics, Inc. Common Stock's earnings last quarter? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) released its earnings results on Wednesday, May, 13th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.23. When did Damora Therapeutics, Inc. Common Stock's stock split? Damora Therapeutics, Inc. Common Stock's stock reverse split before market open on Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Damora Therapeutics, Inc. Common Stock? Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI). Company Calendar Last Earnings5/13/2026Today7/14/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 DMRA's financial health is in the Green zone, according to TradeSmith. DMRA has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DMRA Previous SymbolNASDAQ:GLTO CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Damora Therapeutics, Inc. Common Stock$42.43 High Price Target$46.00 Low Price Target$35.00 Potential Upside/Downside+51.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-428.30% Return on Assets-114.62% Debt Debt-to-Equity RatioN/A Current Ratio22.49 Quick Ratio22.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($110.11) per share Price / Book-0.25Miscellaneous Outstanding Shares61,550,000Free Float61,307,000Market Cap$1.72 billion OptionableNo Data Beta1.46 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DMRA) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | SponsoredTrump Set to Unleash 219-Year-Old “Super Weapon” on U.S. SoilFour-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...Paradigm Press | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Damora Therapeutics, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Damora Therapeutics, Inc. Common Stock With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMRA Stock Alerts